Cellular Senescence: a Double-edged Sword in Cancer Therapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Sep 29

PMID 37771436

Authors

Shuai Xiao

Dongmin Qin

Xueyang Hou

Lingli Tian

Yeping Yu

Rui Zhang

Hao Lyu

Dong Guo

Xing-Zhen Chen

Cefan Zhou

Jingfeng Tang

Affiliations

Soon will be listed here.

Abstract

Over the past few decades, cellular senescence has been identified in cancer patients undergoing chemotherapy and radiotherapy. Senescent cells are generally characterized by permanent cell cycle arrest as a response to endogenous and exogenous stresses. In addition to exiting the cell cycle process, cellular senescence also triggers profound phenotypic changes such as senescence-associated secretory phenotype (SASP), autophagy modulation, or metabolic reprograming. Consequently, cellular senescence is often considered as a tumor-suppressive mechanism that permanently arrests cells at risk of malignant transformation. However, accumulating evidence shows that therapy-induced senescence can promote epithelial-mesenchymal transition and tumorigenesis in neighboring cells, as well as re-entry into the cell cycle and activation of cancer stem cells, thereby promoting cancer cell survival. Therefore, it is particularly important to rapidly eliminate therapy-induced senescent cells in patients with cancer. Here we review the hallmarks of cellular senescence and the relationship between cellular senescence and cancer. We also discuss several pathways to induce senescence in tumor therapy, as well as strategies to eliminate senescent cells after cancer treatment. We believe that exploiting the intersection between cellular senescence and tumor cells is an important means to defeat tumors.

Citing Articles

Molecular principles underlying aggressive cancers.

Nussinov R, Yavuz B, Jang H Signal Transduct Target Ther. 2025; 10(1):42.

PMID: 39956859 PMC: 11830828. DOI: 10.1038/s41392-025-02129-7.

Inhibition of miMOMP-induced SASP to combat age-related disease.

Liao X, Guo Z, He M, Zhang Y Front Aging. 2025; 6:1505063.

PMID: 39944655 PMC: 11814426. DOI: 10.3389/fragi.2025.1505063.

Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation.

Hwang H, Kang D, Shin J, Jung J, Ko S, Jung K Nat Commun. 2025; 16(1):353.

PMID: 39753537 PMC: 11699195. DOI: 10.1038/s41467-024-54132-1.

Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: Genes Address Common Hub Genes and Drugs.

Ayna Duran G Eur J Breast Health. 2025; 21(1):63-73.

PMID: 39744927 PMC: 11706122. DOI: 10.4274/ejbh.galenos.2024.2024-11-2.

Targeting cellular senescence in kidney diseases and aging: A focus on mesenchymal stem cells and their paracrine factors.

Hejazian S, Hejazian S, Mostafavi S, Hosseiniyan S, Montazersaheb S, Ardalan M Cell Commun Signal. 2024; 22(1):609.

PMID: 39696575 PMC: 11657437. DOI: 10.1186/s12964-024-01968-1.

References

Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

Chondrogianni N, Stratford F, Trougakos I, Friguet B, Rivett A, Gonos E . Central role of the proteasome in senescence and survival of human fibroblasts: induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation. J Biol Chem. 2003; 278(30):28026-37. DOI: 10.1074/jbc.M301048200. View

Ahmad S, Duke S, Jena R, Williams M, Burnet N . Advances in radiotherapy. BMJ. 2012; 345:e7765. DOI: 10.1136/bmj.e7765. View

Guan X, LaPak K, Hennessey R, Yu C, Shakya R, Zhang J . Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth. Mol Cancer Res. 2017; 15(3):237-249. PMC: 5334447. DOI: 10.1158/1541-7786.MCR-16-0319. View

Roberson R, Kussick S, Vallieres E, Chen S, Wu D . Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 2005; 65(7):2795-803. DOI: 10.1158/0008-5472.CAN-04-1270. View

Laberge R, Sun Y, Orjalo A, Patil C, Freund A, Zhou L . MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015; 17(8):1049-61. PMC: 4691706. DOI: 10.1038/ncb3195. View

Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian C, Roberto M . Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2016; 66(7):1286-1296. PMC: 5512174. DOI: 10.1136/gutjnl-2016-312268. View

Sharpless N, Sherr C . Forging a signature of in vivo senescence. Nat Rev Cancer. 2015; 15(7):397-408. DOI: 10.1038/nrc3960. View

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

10.

Coppe J, Desprez P, Krtolica A, Campisi J . The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5:99-118. PMC: 4166495. DOI: 10.1146/annurev-pathol-121808-102144. View

11.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

12.

Qian Y, Chen X . Senescence regulation by the p53 protein family. Methods Mol Biol. 2013; 965:37-61. PMC: 3784259. DOI: 10.1007/978-1-62703-239-1_3. View

13.

Lehmann M, Korfei M, Mutze K, Klee S, Skronska-Wasek W, Alsafadi H . Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis . Eur Respir J. 2017; 50(2). PMC: 5593348. DOI: 10.1183/13993003.02367-2016. View

14.

Ghebranious N, Donehower L . Mouse models in tumor suppression. Oncogene. 1999; 17(25):3385-400. DOI: 10.1038/sj.onc.1202573. View

15.

Serrano M, Lin A, McCurrach M, Beach D, Lowe S . Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88(5):593-602. DOI: 10.1016/s0092-8674(00)81902-9. View

16.

Kang T, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D . Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011; 479(7374):547-51. DOI: 10.1038/nature10599. View

17.

Lowe S, Cepero E, Evan G . Intrinsic tumour suppression. Nature. 2004; 432(7015):307-15. DOI: 10.1038/nature03098. View

18.

Izumi-Nakaseko H, Fujiyoshi M, Hagiwara-Nagasawa M, Goto A, Chiba K, Kambayashi R . Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors. Cardiovasc Toxicol. 2019; 20(1):58-70. DOI: 10.1007/s12012-019-09538-5. View

19.

Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M . Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 2014; 9(1):75-89. DOI: 10.1016/j.celrep.2014.08.044. View

20.

Montero J, Letai A . Why do BCL-2 inhibitors work and where should we use them in the clinic?. Cell Death Differ. 2017; 25(1):56-64. PMC: 5729538. DOI: 10.1038/cdd.2017.183. View